CSF2 and triple-negative breast carcinoma: In a recent study, a peritumorally injected pore-forming alginate gel loaded with granulocyte-macrophage colony-stimulating factor (GM-CSF) and doxorubicin-iRGD (Dox-iRGD) conjugate significantly improved the antitumor efficacy against poorly immunogenic triple negative breast cancer (4T1) model [235].